CMS has released information on ACA provisions that require a new minimum Medicaid rebate of 17.1% of the average manufacturer price (AMP), effective January 1, 2010, for drugs approved by the FDA exclusively for pediatric indications and for blood clotting factors. CMS also has released listings of the specific drugs impacted by these provisions. CMS also has issued Medicaid Drug Rebate Program Release No. 81, which, among other things, provides updated information on the new Medicaid rebate calculation for Single Source/Innovator Multiple Source line extension drugs in an oral solid dosage form.